Patrick Eimerman

Company: Saga Diagnostics AB

Job title: Vice President - Business Development & Partnerships

Seminars:

Increasing Access to ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs 12:45 pm

A disruptive, low-cost approach to MRD detection and quantification using WGS and a proprietary dPCR platform Structural Variants (SVs) are the ideal pan-cancer biomarker for determining MRD status using dPCR Increased analytical sensitivity demonstrates improved clinical performanceRead more

day: Day Two Track A